This includes USD 2 billion of new investment creating more than a thousand new, high-skilled jobs contributing to the growth of the US economy, the company states.

AstraZeneca’s expanding footprint in the US includes an R&D centre in Kendall Square, Cambridge, Massachusetts, a next generation manufacturing facility for biologics in Maryland, a cell therapy manufacturing capacity on the West and East Coasts, and a specialty manufacturing in Texas

“Our multibillion dollar investment reflects the attractiveness of the business environment together with the quality of talent and innovation capabilities here in the United States. By expanding our R&D and manufacturing footprint, we aim to enhance the development of cutting-edge therapies and support the United States leadership in healthcare innovation,” says Pascal Soriot, Chief Executive Officer, AstraZeneca.

Ambition 2030

These US investments are the first of a series of important steps to help deliver AstraZeneca’s ambition to achieve USD 80 billion in Total Revenue by 2030 as set out in May this year. A key element of its strategy is accelerating its development in the United States. The US is AstraZeneca’s largest market, generating 44% of its Total Revenue, states the company.